📢 French drug maker Seabelife SAS has received a €1.5m grant to develop a new drug for geographic atrophy, an advanced form of dry AMD. The drug, SBL03, blocks two forms of regulated necrosis that lead to cell death and vision loss. Seabelife aims to have a treatment ready for clinical trials by Q1/2026.
📢 Breakthrough Drug for Vision Loss: Seabelife’s Next-Gen AMD Treatment
Introduction:
French drug maker Seabelife SAS has received a €1.5 million fund to develop a new dual-acting necroptosis blocker for the treatment of geographic atrophy, an advanced form of dry age-related macular degeneration (AMD).
Main points:
- Seabelife SAS has received a €1.5 million fund to develop a new drug for geographic atrophy, a form of dry AMD.
- The drug, SBL03, is a derivative of a naturally occurring flavanone and has been shown to block two forms of regulated necrosis that lead to photoreceptor cell death and vision loss.
- The company aims to develop a topical formulation of the drug as an alternative to intravitreal injections.
- SBL03 has the potential to fight both necroptosis and ferroptosis, two forms of cell death that contribute to vision loss in AMD.
Conclusion:
Seabelife SAS is developing a new drug, SBL03, to treat geographic atrophy, a form of dry AMD. The drug has shown promise in blocking two forms of regulated necrosis that contribute to cell death and vision loss. The company aims to develop a topical formulation of the drug as an alternative to current treatment options. This funding allows Seabelife SAS to further advance the development of this next-generation dry AMD drug.
